Cross-Border Applications and Commercial Prospects of Microneedle Technology

As an innovative transdermal delivery platform, microneedle technology is rapidly breaking the boundaries of traditional medical sectors and expanding into consumer health, aesthetic skincare, and vaccination scenarios. This technology can precisely regulate the release of growth hormones in accordance with the body's inherent biological rhythms, thereby offering an entirely new solution for the clinical treatment of endocrine system-related diseases. In February of the same year, another groundbreaking study successfully integrated medical data storage functions and mRNA therapeutic technologies onto a unified microneedle platform, achieving a pioneering breakthrough in the simultaneous delivery of personal medical records and mRNA drugs within the human body.

Diabetes management has emerged as a pivotal application direction for dissolvable microneedle technology. A research study published in Nature Biomedical Engineering in August 2025 made a breakthrough in addressing the core challenge of long-term antibody stability in wearable biosensors. By developing a microneedle patch capable of continuous monitoring of blood glucose and insulin levels, the technology enables real-time dynamic tracking of diabetic patients' glycemic indicators, alongside precise regulation and on-demand insulin delivery. This integrated monitoring and treatment solution greatly enhances medication convenience for patients and substantially alleviates puncture pain and discomfort caused by conventional injections. Industry forecasts indicate that by 2025, the market scale of dissolvable microneedle drug delivery systems in China is expected to exceed 5 billion RMB, with the annual compound growth rate maintaining above 30%.

In the field of aesthetic skincare, microneedle technology is revolutionizing the form and user experience of traditional skincare products. A study released in Advanced Materials in March 2025 developed a novel galvanic cell-driven microneedle patch. Through the chemical reaction between magnesium and water, the patch sustainably generates hydrogen, microcurrents and magnesium ions locally on the skin, effectively reversing photoaging-induced wrinkles. In terms of commercialization, Wuxi Zhentai Biotechnology launched a dissolvable microcrystal antipruritic and soothing patch, introducing medical-grade microcrystal technology into daily household skincare scenarios for the first time. On a circular patch approximately 1 centimeter in diameter, an array of 135 transparent ultra-fine microneedles, thinner than human hair, is evenly distributed. These conical microneedles feature a length of around 300 micrometers, a base diameter of 100 micrometers, and an ultra-fine tip measuring merely 15 micrometers, delivering outstanding performance of instant active ingredient penetration and rapid efficacy.

Within trichology and hair medical treatment, microneedle hair transplantation technology has undergone five major technical upgrades. As a continuous innovator driving microneedle iteration in China's hair healthcare industry, Dama Microneedle Hair Transplant has stabilized the survival rate of transplanted hair follicles at over 95%. In 2025, Dama introduced AI hair harvesting robots and launched synchronized clinical trials in Beijing, Shanghai, Guangzhou and Shenzhen. Preliminary data proves that the robots deliver excellent efficiency and precision in hair follicle extraction, poised to establish an efficient man-machine collaborative surgical model with clinicians.

In oncology treatment, a study published in Journal of the American Chemical Society in June 2025 developed a CD47 targeted peptide-LYTAC microneedle delivery system. This system specifically degrades CD47 proteins on tumor cell surfaces via the lysosomal pathway, avoiding adverse reactions such as erythrocyte toxicity triggered by conventional antibody therapies and providing an innovative approach for tumor immunotherapy. Another research project constructed a spatiotemporally controllable sonogenetic therapy microneedle platform, which enhances the efficiency of the CRISPRa gene editing system through ultrasonic stimulation and explores its application in obesity treatment.

In terms of financing activities, the microneedle sector secured multiple major capital investments in 2025. Zhonghui Pharmaceutical, focusing on hollow microneedle research and development, completed a financing of nearly 50 million RMB in June. Mingche Technology, an ophthalmic innovative medical device enterprise with proprietary microneedle platforms, closed a multi-million-yuan Series A financing in November. Listed enterprises are also accelerating the layout and industrial implementation of microneedle technology. For instance, Sailong Pharmaceutical entered a strategic cooperation with Zhongke Microneedle to jointly build a joint research laboratory.

Regarding product approval and launch, a growing number of innovative microneedle products have been successively rolled out worldwide. In June 2025, Aidixink (Suzhou) Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of NASDAQ-listed Aidixink Biotech, obtained FDA certification for a new product in the same series of its OTC dissolvable microneedle drug MICROEPAD™, officially registering and launching the product in the U.S. market. This milestone marks the formal entry of China's independently developed microneedle technology into the global marketplace.

The cross-border integrated applications of microneedle technology not only continuously expand its market boundaries, but also strongly foster the improvement and maturity of the entire industrial ecosystem. From breakthroughs in smart responsive materials and multi-scenario clinical transformation, to precise drug delivery and minimally invasive diagnosis and treatment, microneedle technology is transitioning from laboratory-based innovative research into a period of accelerated industrial-scale application. Every technical iteration reflects refined craftsmanship, and more importantly, embodies the in-depth commitment and persistent pursuit of optimizing patient experience, advancing medical equity, and improving overall quality of life.